Insmed | INSM - Stammkapital

Aktienkurs
109.10
Täglich Wechseln
-6.52 -5.64%
Monatlich
-23.59%
Jährlich
60.16%
Q2 Prognose
99.25




Stammkapital Veränderung Datum
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
DBV Technologies USD 136.82M 51.98K 2025-09
Gilead Sciences USD 1.24B 1000K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 216.52M 2.27M 2026-03
Novartis USD 1.91B 10.64M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03